title: Octreotide in refractory functional epigastric pain with nutritional impairment--an open study.
abstract: OBJECTIVE
  To test the therapeutic efficacy of octreotide administered subcutaneously for the relief of chronic refractory epigastric pain severe enough to provoke nutritional impairment.
  
  
  METHODS
  Seventeen patients were enrolled in an open trial. Epigastric pain had lasted from 1 to 8 years (median: 5 years), following anti-reflux surgery in eight patients. Median weight loss was 10% (range 10-15). The initial dose of octreotide was 50 microgram b.d, adjusted during the follow-up visits which were scheduled for months 1, 3, 6, 8, 10, 12 and every 3 months. At each visit, overall symptomatic improvement, frequency and intensity of symptoms were checked on a 10-cm visual analogic scale.
  
  
  RESULTS
  At month 1, a progressive improvement of pain intensity was reported in 15 of the 17 patients, while octreotide was a therapeutic failure in two. In four out of 15, the daily dose of octreotide was increased to 100 microgram b.d. In these 15 patients, median follow-up was 7 months (3-27). The symptomatic benefit was maintained in each patient at month 3, with a median weight gain of 3.5 kg.2-5 An attempt to stop octreotide led to recurrence of symptoms in 2-3 days which were as intense as before the treatment. The 11 patients followed-up for at least 6 months reported persistent improvement of symptoms with octreotide and a median weight gain of 4 kg.3-7 Four patients were followed up for more 11-27 months: octreotide was withdrawn gradually in two who remained asymptomatic. Six of the 17 patients experienced minor side-effects, but none developed biliary sludge.
  
  
  CONCLUSIONS
  This open study suggests that octreotide could be a promising alternative treatment when all others fail in refractory chronic functional epigastric pain severe enough to limit food intake and to induce nutritional impairment. These results must be tested by a placebo-controlled study.
authors.affiliation: Digestive Tract Research Group, Rouen University Hospital, Rouen, France. philippe.ducrotte@chu-rouen.fr
authors.forename: P
authors.initials: P
authors.lastname: Ducrotte
authors.forename: C
authors.initials: C
authors.lastname: Maillot
authors.forename: A M
authors.initials: AM
authors.lastname: Leroi
authors.forename: O
authors.initials: O
authors.lastname: Lalaude
authors.forename: R
authors.initials: R
authors.lastname: Colin
authors.forename: P
authors.initials: P
authors.lastname: Denis
mesh_terms: D000328:Adult; D000368:Aged; D002908:Chronic Disease; D003680:Deglutition Disorders / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D010148:Intractable Pain / Q000150:complications / Q000188:drug therapy*; D011446:Prospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome; D015431:Weight Loss
chemical_list: D005765:Gastrointestinal Agents; D015282:Octreotide